103 Diagnostic utility of molecular and imaging biomarkers 2 other inclusion & exclusion criteria FNAC sample BRAFV600E / BRAFK601E molecular technique palpable TN; histologic f/u available liquid based FNAC n.s. direct DNA sequencing versus colorimetric mutation detection method (TrimGen). Results in indeterminate cases equal for both methods. TN; histological f/u available FNAC smear BRAFV600E mutant AS-PCR amplification, re-examined ≥2 times. internal controls: direct sequencing of subset of positive and negative samples. TN; indeterminate cytology on two consecutive FNACs; histological f/u available additional FNAC aspirate BRAFV600E AS-PCR TN; FNAC slides and histological f/u available archived FNAC slides BRAFV600E direct DNA sequencing versus pyrosequencing incidental TN on imaging studies; >1cm or <1cm with suspicious US features FNAC needle washout BRAFV600E pyrosequencing TN; ≥2 FNAC slides available; histological f/u available archived FNAC slides BRAFV600E PCR and direct sequencing TN; histological f/u available additional preoperative US-FNAC n.o.s. BRAFV600E +BRAFK601E 2x PCR master mix TN; FNAC sample with adequate nucleic acids FNAC sample n.o.s. BRAFV600E PCR and direct sequencing TN; sufficient DNA quality and quantity; histological f/u available residual material of thin-layer processed specimens BRAFV600E PCR and SSCP analysis TN; sufficient DNA quality and quantity; histological f/u available FNAC needle washout BRAFV600E PCR and SSCP analysis TN; histological f/u available scraped FNAC slides BRAFV600E PCR and pyrosequencing TN; FNAC with sufficient epithelial cells and nucleic acids for molecular analysis; histological f/u available residual material from FNAC and needle washout BRAFV600E miRinform® Thyroid Test TN; histological f/u available MGG-stained FNAC slides BRAFV600E PCR and direct sequencing single TN or TN with suspicious US features; histological f/u available n.s. BRAFV600E mutant AS-PCR amplification and direct sequencing TN; histological f/u available additional FNAC aspirate BRAFV600E pyrosequencing using quantitative data and ROC curve analysis solitary TN >15mm or non-solitary TN with suspicious US features; adequate DNA amplification FNAC needle washout BRAFV600E PCR and restriction length polymorphism (RFLP), plus direct sequencing in positive samples TN; suspicious on US FNAC needle washout BRAFV600E AS-PCR and direct sequencing suspicious TN >5mm, FNAC sample positive for thyroglobulin FNAC needle washout BRAFV600E +BRAFK601E HRM analysis and direct sequencing TN; size ≥4mm FNAC needle washout BRAFV600E PCR, direct sequencing, and real-time exonucleasemediated allelic discrimination (READ) technique TN; histological f/u available FNAC needle washout BRAFV600E PCR and direct sequencing TN; histological f/u available FNAC needle washout BRAFV600E PCR and SSCP analysis TN; clinically or radiologically suspicious; (histological) f/u available FNAC needle washout BRAFV600E DPO-PCR US-confirmed TN ≥1cm; adequate RNA sample and timely shipping for GEC testing (subset of Alexander et al. 2012 with ≥30ng of DNA) 1 or 2 additional FNAC aspirates BRAFV600E AS-PCR TN; (histological) f/u available FNAC needle washout BRAFV600E DPO-PCR TN; no Hürthle cell cytology; histological f/u available FNAC needle washout BRAFV600E +BRAFK601E miRInform® Thyroid Test TN; US-FNAC; histological f/u FNAC needle washout BRAFV600E PCR and direct sequencing adult with TN ≥1cm; FNAC with sufficient nucleic acids for molecular analysis; correct specimen handling and shipping; no duplicate or contaminated specimen additional FNAC aspirate BRAFV600E miRinform® Thyroid Test TN n.o.s. FNAC smears BRAFV600E real-time PCR with primers TN; air-dried FNAC slide available; histological f/u and FFPE samples available for mutation analysis air-dried FNAC smears BRAFV600E +BRAFK601E HRM analysis and pyrosequencing
RkJQdWJsaXNoZXIy MTk4NDMw